Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Microbial Immunity and Vaccines

Protection against Pseudomonas aeruginosa Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of P. aeruginosa

Brian M. Price, Darrell R. Galloway, Neil R. Baker, Linda B. Gilleland, John Staczek, Harry E. Gilleland Jr.
Brian M. Price
Department of Microbiology, The Ohio State University, Columbus, Ohio 43210, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darrell R. Galloway
Department of Microbiology, The Ohio State University, Columbus, Ohio 43210, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil R. Baker
Department of Microbiology, The Ohio State University, Columbus, Ohio 43210, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda B. Gilleland
Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Staczek
Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry E. Gilleland Jr.
Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.69.5.3510-3515.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The Pseudomonas aeruginosa major constitutive outer membrane porin protein OprF, which has previously been shown to be a protective antigen, was targeted as a DNA vaccine candidate. TheoprF gene was cloned into plasmid vector pVR1020, and the plasmid vaccines were delivered to mice by biolistic (gene gun) intradermal inoculation. Antibody titers in antisera from immunized mice were determined by enzyme-linked immunosorbent assay, and the elicited antibodies were shown to be specifically reactive to OprF by immunoblotting. The immunoglobulin G (IgG) immune response was predominantly of the IgG1 isotype. Sera from DNA vaccine-immunized mice had significantly greater opsonic activity in opsonophagocytic assays than did sera from control mice. Following the initial immunization and two consecutive boosts, each at 2-week intervals, protection was demonstrated in a mouse model of chronic pulmonary infection byP. aeruginosa. Eight days postchallenge, both lungs were removed and examined. A significant reduction in the presence of severe macroscopic lesions, as well as in the number of bacteria present in the lungs, was seen. Based on these findings, genetic immunization withoprF has potential for development as a vaccine to protect humans against infection by P. aeruginosa.

Pseudomonas aeruginosa,an opportunistic pathogen, is a leading cause of life-threatening infections in immunocompromised individuals. It is an etiological agent of bacteremia, urinary tract infections, and pneumonia in such patients. The mortality from bacteremia and pneumonia caused byP. aeruginosa infections can exceed 50%. Each year, over two million patients develop hospital-associated infections, and an estimated 88,000 patients die as a result. A report on nosocomial infection surveillance places P. aeruginosa among the three most frequently reported nosocomial pathogens (26).P. aeruginosa is also the cause of chronic, serious pulmonary infection in cystic fibrosis patients. Recent reports listP. aeruginosa among the most serious antibiotic-resistant bacteria and one for which effective vaccines are needed (11, 42).

The observation that genetic immunization, more commonly referred to as DNA vaccination, is able to elicit an immune response has fostered a new generation in vaccine development (37, 49, 50). Production of an effective immune response against selected target antigens has been successfully demonstrated using recombinant retroviral vectors, encapsulation of DNA in liposomes, DNA-coated gold particles introduced by particle bombardment (29, 54), and pure plasmid DNA (naked DNA) injected into muscle tissue in mice (12, 49). DNA immunization has been used to elicit protective antibody and cell-mediated immune responses in a wide variety of preclinical animal models for viral and bacterial diseases (14, 15). The antigen is produced in vivo by the host and is appropriately presented on major histocompatibility complex I or II molecules (2, 6, 8). DNA vaccination represents a novel way to induce a specific immune response in a host organism. DNA vaccines compared to earlier generations of vaccines have many advantages, such as ease of construction, low cost of mass production, high-temperature stability, and ability to induce many different long-lasting immune responses, including cytotoxic T cells as well as recognition by B cells to induce antibody production.

Vaccination with outer membrane protein antigens has been shown to be efficacious against P. aeruginosa infection in a number of studies using killed whole cells (9), purified outer membrane preparations (32, 33), isolated outer membrane proteins (18, 20, 39, 53), protein fusions (38), or synthetic peptides representing protective epitopes (22, 23). The P. aeruginosa major constitutive porin protein, OprF, which has previously been shown to be antigenic (3, 20, 25) and has high homology amongPseudomonas strains (18, 34, 40), was chosen as a vaccine target. This protein has been shown to provide protection in a mouse model of systemic infection (20), a mouse burn infection model (39), and rodent models of acute (28) and chronic lung infection (18, 47). Based on these previous findings, we designed and tested the efficacy of a DNA vaccine based upon outer membrane protein F for immunoprotection against P. aeruginosa.

The eukaryotic expression plasmid pVR1020 (Vical, Inc., San Diego, Calif.) was used in this study (Fig. 1). This plasmid contains an immediate-early cytomegalovirus promoter to ensure efficient expression in a eukaryotic host as well as the human tissue plasminogen activator secretion signal to facilitate secretion of the target antigen (OprF) from the eukaryotic cell (31, 45). The 977-bp oprF gene was cloned fromP. aeruginosa PAO1 genomic DNA using a Taqpolymerase core kit (Qiagen, Inc., Santa Clarita, Calif.) with primers engineered with BamHI- and BglII-cut sites at the 5′ and 3′ ends, respectively. This PCR product and pVR1020 were digested with BamHI and BglII. The plasmid was subsequently dephosphorylated with calf intestinal alkaline phosphatase, and the resulting products were ligated with T4 DNA ligase (Life Technologies, Gaithersburg, Md.). The resulting plasmid, pVR1020/oprF, was transformed into Escherichia coli DH5α, purified by anion-exchange chromatography using Qiagen-tip 2500, and resuspended in cell culture-grade phosphate-buffered saline (PBS) (Life Technologies) to a final concentration of 1 mg/ml.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Construction of plasmids for DNA immunization. (a) Plasmid pVR1020, a eukaryotic expression vector, was used as the negative control for immunization. Kanr, kanamycin resistance gene; CMV promoter, cytomegalovirus immediate-early promoter; CMV intron A, intron A of the CMV immediate-early promoter; hTPA, human tissue plasminogen activator secretion signal; BGH term/p(A), bovine growth hormone terminator and polyadenylation sequence. (b) oprF was cloned into pVR1020 using theBamHI restriction endonuclease site, resulting in the plasmid pVR1020/oprF, which was used as the DNA vaccine for immunization.

Initial experiments were performed to compare the effectiveness of the pVR1020/oprF vaccine administered either by gene gun or by intramuscular (i.m.) inoculation. Inoculation by gene gun yielded results superior to i.m. inoculation in that i.m. inoculation elicited reactive antibodies at a lower rate and to a lower final titer, with the elicited antibodies being less opsonic and nonprotective than gene gun-elicited antibodies. Thus, our preliminary results agreed with previous reports (4, 5, 17, 55) that gene gun inoculation is superior to i.m. inoculation. We therefore adopted gene gun inoculation as the route of immunization for our standard procedure.

Mice (5-week-old, female, specific-pathogen-free ICR mice) were obtained from Harlan Sprague-Dawley, Indianapolis, Ind. All mice were housed in the Animal Resources Facility at Louisiana State University Health Sciences Center-Shreveport and handled according to American Association for Laboratory Animal Sciences guidelines. At 14-day intervals, groups of 30 mice were inoculated a total of three times in the abdomen via biolistic particle injection (Helios Gene Gun kit; Bio-Rad, Richmond, Calif.) on days 0, 14, and 28 with 2 μg of either pVR1020 (control) or pVR1020/oprF, which was used to coat 1-μm-diameter gold beads. Serum samples were taken from nonimmunized mice on day zero and from each immunized group on days 14, 28, and 42.

To obtain sera for use in the opsonophagocytic assays, mice were immunized with protein F purified from the PAO1 strain as previously described (20). Each mouse was immunized with four doses of 10 μg of protein F given i.m. in alternate hips at 2-week intervals, with aluminum hydroxide used as adjuvant for the first and second doses and no adjuvant included for the last two doses. Two weeks after the last immunization, the mice were bled and the serum samples obtained were pooled for use in the assay.

To demonstrate that pVR1020/oprF was expressed in eukaryotic cells, human melanoma UM449 cells were transiently transfected using Lipofectin (Life Technologies) (36). Briefly, cells were transfected in duplicate with 2 μg of either pVR1020/oprFor pVR1020. Following 48 h of incubation, the culture medium was removed from the UM449 cell layers and the supernatant fraction resulting from centrifugation (10,000 × g for 10 min at 4°C) of that culture medium was used for immunoblot analysis to detect in situ synthesis of OprF from pVR1020/oprF. The cell layer was washed once in PBS. The cells were resuspended in PBS and lysed in sodium dodecyl sulfate-polyacrylamide gel electrophoreis sample buffer prior to use in immunoblot analysis. The immunoblot protocol has been described previously (24).

All bacterial strains used in this study were grown at 30°C with shaking in BBL nutrient broth (Becton-Dickinson Microbiological Systems, Cockeysville, Md.) or on nutrient agar (Difco Laboratories, Detroit, Mich.) plates. The following strains of P. aeruginosa were used: Fisher-Devlin (FD) immunotype 1 (ATCC 27584; Difco 0–6), FD immunotype 2 (ATCC 27313; Difco 0–11), FD immunotype 3 (ATCC 27314; Difco 0–2), FD immunotype 4 (ATCC 27315; Difco 0–1), FD immunotype 5 (ATCC 27585; Difco 0–10), FD immunotype 6 (ATCC 27579; Difco 0–7 and 0–8), FD immunotype 7 (PAO1; Difco 0–5), and KG1077, which is a protein F-deficient mutant of PAO1.

Polyclonal antiserum specificity in immunized mice was subjected to immunoblot analysis against P. aeruginosa PAO1 cell lysates using antisera diluted 1:1,000 as previously described (13). Nitrocellulose membranes were blocked in 2% (wt/vol) nonfat milk in 0.1% Tween 20–Tris-buffered saline and probed with polyclonal mouse sera from immunized mice. The membrane was washed three times in 1% Tween 20–Tris-buffered saline, and rabbit anti-mouse immunoglobulin (Ig) conjugated to horseradish peroxidase (Amersham Life Science, Arlington Heights, Ill.) was added as a secondary antibody. Reactive polypeptides were detected using a chemiluminescent substrate (National Diagnostics, Inc., Atlanta, Ga.) and visualized on film.

Sera recovered from DNA vaccine-immunized and control mice were analyzed by enzyme-linked immunosorbent assay (ELISA) for reactivity against bacterial cells, OprF peptides 9 (14 mer) and 10 (14 mer) (27), and purified protein F according to published procedures (27, 39). The wells of microtiter plates (polyvinyl chloride or Immulon 1 [Dynatech, Chantilly, Va.]) were coated with either bacterial whole cells of KG1077 or each FD immunotype strain, 2.5 μg of synthetic peptide 9 (14 mer), 2.5 μg of synthetic peptide 10 (14 mer), or 10 μg of protein F. Dilutions of sera pooled from similarly immunized mice were incubated with the prepared microtiter plate at 37°C for 1 h. Bound IgG was detected by alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotechnology Assoc. Inc., Birmingham, Ala.) usingp-nitrophenylphosphate (Sigma-Aldrich, St. Louis, Mo.) as the substrate. Endpoint titers for P. aeruginosa whole cell-, peptide-, or protein F-specific antibodies were expressed as the inverse of the dilution that gave a mean value for the optical density at 405 nm (OD405) greater than the OD405 of a 1:50 dilution of normal mouse serum obtained from unimmunized mice. All sera were analyzed in at least two separate assays.

Antibody isotypes in antisera from immunized mice were analyzed by ELISA as previously described (52) as modified by Abdillahi and Poolman (1). Briefly, Immulon 3 plates (Dynatech) were coated with 100 μl of whole P. aeruginosaPAO1 cells suspended in PBS at an OD620 of 0.09. Plates were then placed at 37°C overnight to allow the buffer to evaporate. Serum samples were serially diluted in PBS containing 0.025% Tween 20 and added to the plate; anti-mouse IgG1 or anti-mouse IgG2a conjugated to alkaline phosphatase was used as the secondary antibody (Zymed Laboratories, Inc., San Francisco, Calif.). The presence of bound antibody was detected usingp-nitrophenylphosphate (Sigma) as the substrate, with absorbance read at 410 nm on a Bio-Rad model 550 plate reader. Antibody quantitation was determined by ELISA analysis using a standard curve with purified IgG2a and IgG1 antibody reagents (Zymed Laboratories, Inc.).

Sera from DNA vaccine-immunized mice taken 14 days after the last immunization and from control mice were tested for the ability to mediate the opsonophagocytic uptake of P. aeruginosa by human polymorphonuclear leukocytes (PMNs) as described previously (19). All sera were heated at 56°C for 30 min to inactivate complement. Cultures of FD immunotype 2 and 4 strains were diluted to a cell density of 108 cells/ml for use in the assay. The reaction mixtures included 50 μl of bacterial culture plus 50 μl of serum. These mixtures were incubated for 30 min at 37°C with shaking. Then, 100 μl of human venous blood was added to each mixture, and this final combination was incubated for 30 min at 37°C with shaking. Blood smears were prepared from each of the reaction mixtures and stained with Giemsa stain. For each assay three slides per reaction mixture were examined microscopically, and the number of bacterial cells contained within the first 75 isolated, intact PMNs encountered (25 PMNs per slide) was determined for each reaction mixture. Each assay was performed in triplicate and the results were combined to yield a total of 225 PMNs counted for each reaction mixture. The number (mean ± standard deviation) of bacterial cells per PMN was calculated. Statistical analyses of the differences in the opsonophagocytic uptake of bacteria by PMNs were performed by comparing the means by the unpaired two-tailed Studentt test using a Pro-Stat program.

The immunoprotective potential of the DNA vaccine was tested in a mouse model of chronic pulmonary infection (7, 18, 47, 48). Two weeks after the final immunization, the mice were challenged with agar beads containing the P. aeruginosa FD immunotype 4 strain. The mice were first anesthetized with an intraperitoneal injection of sodium pentobarbital and then inoculated via a tracheal incision with 50 μl of an agar bead slurry encasing approximately 7 × 102 CFU of P. aeruginosa. A beaded-tip 22-gauge needle was gently guided to favor inoculation of the left lung. The incision was closed with sterile wound clips. Eight days after the challenge, protection afforded to the immunized mice by the DNA vaccine was assessed by two methods. First, the lungs were examined macroscopically for the presence of lesions (7, 18, 47) according to the following scoring scheme: 0, absense of any macroscopic lesion; 1+, presence of one or two small lesions not exceeding 1 mm in diameter; 2+, presence of three or more small lesions not exceeding 1 mm in diameter; 3+, presence of a medium lesion 2 to 5 mm in diameter; and 4+, presence of a large lesion exceeding 5 mm in diameter. Scoring of the pulmonary lesions was done by an investigator with more than 15 years of experience in macroscopic lung lesion scoring. Second, bacterial quantitation of the number of P. aeruginosa cells present in the lungs was performed as described previously (7, 18). Briefly, both lungs were aseptically removed and homogenized in a 1:10 (wt/vol) dilution of sterile saline with a tissue grinder. Dilutions of these lung tissues were plated onto nutrient agar for quantitative determination of the numbers of P. aeruginosa cells present. The presence of fewer than 5 × 103 CFU was selected as a significant cutoff value because previously it has been shown to represent a >95% (or 2-log) reduction from the mean number of bacteria found in the lungs of challenged control mice 8 days after challenge (47). Duplicate experiments were performed and the results were compiled for analysis. Statistical analyses of the differences in the number of severe lung lesions and in bacterial quantitation between mice immunized with pVR1020 or pVR1020/oprF were performed with the IBM EpiStat Basic Statistics program. P values were calculated by the Fisher exact test, and values of ≤0.05 were considered to be significant.

Production of OprF by eukaryotic cells.To verify expression of the target gene and synthesis of the target protein in mammalian cells, immunoblot analysis of transfected cells was performed. The adherent human melanoma cell line UM449 was transiently transfected with plasmid VR1020/oprF or pVR1020 (negative control). Following a 48-h incubation, culture supernatants and cell lysates were examined by immunoblot analysis with antisera to OprF to detect the presence of OprF. As illustrated in Fig.2, upon transfection with pVR1020/oprF, the protein was found not only in the UM449 cells but also in the supernatant fraction, which was expected since the pVR1020 plasmid is designed to include an N-terminal secretion signal sequence to facilitate translocation of OprF to the endoplasmic reticulum and eventual release from the cell.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Immunoblot of eukaryotic cells with polyclonal anti-OprF mouse sera. Lanes (labeled as follows): Cells, lysed UM449 cells that had been transfected with pVR1020/oprF, incubated for 48 h, washed in PBS, and then resuspended in PBS for lysis; Sup., the initial 48-hour culture supernatant from UM449 cells transfected with pVR1020/oprF; and Control, lysed UM449 cells transfected with pVR1020. Note that OprF was seen predominantly in the pelleted cell fraction but was also found in the supernatant.

Characteristics of elicited antibodies.Sera from pVR1020/oprF-immunized mice were evaluated for the ability to react specifically with protein F from P. aeruginosastrain PAO1. Whereas sera from vector-immunized mice did not react, sera from DNA-vaccinated animals reacted with protein F, F′, and protein H (Fig. 3). Cross-reaction with protein H has been shown previously with sera from mice immunized with protein F (25, 39). Antibody responses induced by gene gun inoculation were predominantly of the IgG1 isotype, indicating a Th2 (humoral) type of immune response as the calculated IgG1:IgG2a ratio was 10.33 (93 ng of IgG1/ml of serum versus 9 ng of IgG2a/ml of serum). This is in agreement with the findings of previous reports (4, 13, 35) that gene gun inoculation with various antigens results in a predominant IgG1 response.

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Immunoblot of proteins extracted from whole cells of the PAO1 strain of P. aeruginosa with polyclonal anti-OprF sera obtained from DNA-immunized (pVR1020/oprF) mice. Note that the antisera reacted at bands corresponding to F (OprF), F′ (denatured OprF), and H (OprH).

The sera from the vector control-immunized mice had no reactivity by ELISA with any of the whole cells of the various strains of P. aeruginosa, with peptides 9 and 10, or with purified protein F. The sera from mice biolistically immunized with the pVR1020/oprF vaccine reacted strongly by ELISA with whole cells of each of the seven FD immunotype strains, with a titer of IgG antibodies against each in the range of 12,800 to 25,600. The sera did not react significantly (titer of 50) with the protein F-deficient KG1077 strain or with protein F peptide 9 or 10 (titer of 100). The sera did react well against purified intact protein F, with titers in the range of 51,200 to 102,400. Thus, biolistic inoculation of mice with the pVR1020/oprF vaccine did elicit a strong IgG antibody response to purified protein F and whole cells of heterologous immunotypes of P. aeruginosa.

Sera from vector control- and pVR1020/oprF-immunized mice were tested for opsonic activity in an opsonophagocytic assay. P. aeruginosacells were mixed with undiluted heat-inactivated sera obtained from the control- and pVR1020/oprF- immunized mice and incubated with human whole blood. The sera recovered from mice immunized with the pVR1020/oprF vaccine mediated opsonophagocytic uptake of P. aeruginosa by PMNs significantly greater than that following exposure to the vector-immunized mouse sera. As shown for the FD 4 strain (Table1), the sera from pVR1020/oprF-immunized mice had an opsonic ratio of 1.34 compared to that of the sera from vector control-immunized mice. This ratio compares favorably with the opsonic ratio of 1.56 obtained for sera from mice immunized with purified protein F versus normal mouse sera (P value for the mean for sera from pVR1020/oprF-immunized mice compared to the mean for sera from protein F-immunized mice is 0.084; i.e., there is no statistically significant difference between these two values). Similar results were obtained for FD 2 cells, which yielded an opsonic ratio of 1.37 for sera from pVR1020/oprF-immunized mice compared to sera from vector control-immunized mice (data not shown).

View this table:
  • View inline
  • View popup
Table 1.

Quantitation of phagocytic uptake by PMNs ofP. aeruginosa FD 4 cells exposed to antisera from immunized mice

Protection in the murine chronic pulmonary infection model.The immunoprotective potential of the pVR1020/oprF vaccine was tested in a mouse model of chronic pulmonary infection. Eight days after challenge with approximately 7 × 102 agar-encased P. aeruginosa FD 4 cells delivered via intratracheal inoculation into the left lung of each mouse, the lungs were removed and examined for evidence of vaccine protection by two means. First, the presence of severe lung lesions, i.e. lesions scored as ≥2+, was determined (Table2). Second, the lungs were assayed to quantitate the number of P. aeruginosa cells present in the lungs (Table 3). The pVR1020/oprF-immunized mice had significantly fewer severe lung lesions (43.2%) than did the vector control-immunized mice (76.2%). A similar reduction in the number of lungs containing >5 × 103 CFU of P. aeruginosawas seen (40.9 and 69% for pVR1020/oprF-immunized mice and vector control-immunized mice, respectively). The number of lungs from which P. aeruginosa had been completely cleared, as indicated by no growth upon quantitation, also was significantly higher in the pVR1020/oprF-immunized mice than in the vector control-immunized mice. Thus, the pVR1020/oprF vaccine afforded significant protection to the immunized mice against subsequent pulmonary challenge with P. aeruginosa.

View this table:
  • View inline
  • View popup
Table 2.

Scoring of macroscopic lung lesions in immunized mice following challenge with FD 4 P. aeruginosa in a chronic pulmonary infection model

View this table:
  • View inline
  • View popup
Table 3.

Quantitation of P. aeruginosa present in the lungs of immunized mice following challenge with FD 4 P. aeruginosa in a chronic pulmonary infection model

Potential of an oprF DNA vaccine against P. aeruginosa infections in humans.Herein, we have reported the successful construction of a DNA vaccine using the oprFgene of P. aeruginosa (Fig. 1). The efficacy of this vaccine in eliciting anti-OprF (Fig. 3), whole cell-reactive, opsonic (Table 1) IgG antibodies of the IgG1 isotype and in affording protection (Tables2 and 3) in a mouse model of chronic pulmonary infection was demonstrated. The DNA vaccine produced results comparable to previously published results for protection obtained in rodent models of chronic pulmonary infection following immunization with purified protein F fromP. aeruginosa (16, 18, 21, 47).

Protection in animal models provides only a suggestion of the potential effectiveness of that vaccine in humans. In the case of a pVR1020/oprF vaccine specifically, additional vaccine components, such as P. aeruginosa PcrV (43), outer membrane protein I (30, 53), or elastase epitopes (46), all of which have previously been shown to be antigenic, might be combined with oprF to augment the final vaccine's effectiveness. Moreover, the effectiveness of the final vaccine in humans may depend on determining the optimal vaccination protocol. This may require using a different DNA vector delivery system or using a combination of delivery systems, such as an attenuatedSalmonella strain (10) or chimeric virus to maximize the immunogenic response in humans. Alternatively, a combination of initial immunization with a DNA oprF vaccine followed by booster immunization(s) with a protein F or protein F epitope peptide vaccine might be required for optimal effectiveness of the vaccine in humans (41, 44). Another consideration is that treatment of Pseudomonas infections in humans will no doubt involve other simultaneous therapeutic modalities, such as antibiotics and pulmonary or respiration therapy, and these additional treatments will influence the outcome of human infections in vaccinated individuals. The results presented in this report using a DNAoprF vaccine for protection against P. aeruginosain a mouse model of chronic pulmonary infection indicates that a DNA vaccine for protection of humans against P. aeruginosainfection warrants continued development.

ACKNOWLEDGMENTS

This research was funded in part by grant RO1-AI44424 from the National Institutes of Health to J.S. and H.E.G. and by a grant from the Shriners' Hospitals for Children (Cincinnati, Ohio) to D.R.G. and N.R.B.

Notes

Editor: A. D. O'Brien

FOOTNOTES

    • Received 2 November 2000.
    • Returned for modification 12 January 2001.
    • Accepted 9 February 2001.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Abdillahi H.,
    2. Poolman J. T.
    Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies.FEMS Microbiol. Lett.481987367371
    OpenUrlCrossRef
  2. 2.↵
    1. Allsopp C. E.,
    2. Plebanski M.,
    3. Gilbert S.,
    4. Sinden R. E.,
    5. Harris S.,
    6. Frankel G.,
    7. Dougan G.,
    8. Hioe C.,
    9. Nixon D.,
    10. Paoletti E.,
    11. Layton G.,
    12. Hill A. V.
    Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization.Eur. J. Immunol.26199619511959
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Battershill J. L.,
    2. Speert D. P.,
    3. Hancock R. E. W.
    Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages.Infect. Immun.55198725312533
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Belperron A. A.,
    2. Feltquate D.,
    3. Fox B. A.,
    4. Horii T.,
    5. Bzik D. J.
    Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum.Infect. Immun.67199951635169
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Bennett A. M.,
    2. Phillpotts R. J.,
    3. Perkins S. D.,
    4. Jacobs S. C.,
    5. Williamson E. D.
    Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan equine encephalitis virus.Vaccine181999588596
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Bohm W.,
    2. Mertens T.,
    3. Schirmbeck R.,
    4. Reimann J.
    Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses.Vaccine161998949954
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Brennan F. R.,
    2. Jones T. D.,
    3. Gilleland L. B.,
    4. Bellaby T.,
    5. Xu F.,
    6. North P. C.,
    7. Thompson A.,
    8. Staczek J.,
    9. Lin T.,
    10. Johnson J. E.,
    11. Hamilton W. D. O.,
    12. Gilleland H. E. Jr.
    Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus.Microbiology1451999211220
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Condon C.,
    2. Watkins S. C.,
    3. Celluzzi C. M.,
    4. Thompson K.,
    5. Falo L. D. Jr.
    DNA-based immunization by in vivo transfection of dendritic cells.Nat. Med.2199611221128
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Cripps A. W.,
    2. Dunkley M. L.,
    3. Clancy R. L.
    Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.Infect. Immun.62199414271436
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Darji A.,
    2. Guzman C. A.,
    3. Gerstel B.,
    4. Wachholz P.,
    5. Timmis K. N.,
    6. Wehland J.,
    7. Chakraborty T.,
    8. Weiss S.
    Oral somatic transgene vaccination using attenuated S. typhimurium.Cell911997765775
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Davies J.
    Bacteria on the rampage.Nature3831996219220
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Davis H. L.,
    2. Michel M. L.,
    3. Mancini M.,
    4. Schleef M.,
    5. Whalen R. G.
    Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen.Vaccine12199415031509
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Denis-K S.,
    2. Mize,
    3. Price B. M.,
    4. Baker N. R.,
    5. Galloway D. R.
    Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A.FEMS Immunol. Med. Microbiol.272000147154
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Donnelly J. J.,
    2. Ulmer J. B.,
    3. Shiver J. W.,
    4. Liu M. A.
    DNA vaccines.Annu. Rev. Immunol.151997617648
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Ertl H. C.,
    2. Xiang Z. Q.
    Genetic immunization.Viral Immunol.9199619
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Fox C. W.,
    2. Campbell G. D. Jr.,
    3. Anderson M. M.,
    4. Zavecz J. H.,
    5. Gilleland L. B.,
    6. Gilleland H. E. Jr.
    Preservation of pulmonary function by an outer membrane protein F vaccine: a study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa.Chest105199415451550
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Fynan E. F.,
    2. Webster R. G.,
    3. Fuller D. H.,
    4. Haynes J. R.,
    5. Santoro J. C.,
    6. Robinson H. L.
    DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.Proc. Natl. Acad. Sci. USA9019931147811482
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Gilleland H. E. Jr.,
    2. Gilleland L. B.,
    3. Matthews-Greer J. M.
    Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.Infect. Immun.56198810171022
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Gilleland H. E. Jr.,
    2. Gilleland L. B.,
    3. Hughes E. E.,
    4. Matthews-Greer J. M.
    Recombinant outer membrane protein F of Pseudomonas aeruginosa elicits antibodies that mediate opsonophagocytic killing, but not complement-mediated bacteriolysis, of various strains of P. aeruginosa.Curr. Microbiol.24199217
    OpenUrlCrossRef
  20. 20.↵
    1. Gilleland H. E. Jr.,
    2. Parker M. G.,
    3. Matthews-Greer J. M.,
    4. Berg R. D.
    Use of purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.Infect. Immun.4419844954
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Gilleland H. E.,
    2. Gilleland L. B.,
    3. Fowler M. R.
    Vacine efficiencies of elastase, exotoxin A, and outer membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model.J. Med. Microbiol.3819937986
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Gilleland H. E. Jr.,
    2. Gilleland L. B.,
    3. Staczek J.,
    4. Harty R.N.,
    5. Garcia-Sastre A.,
    6. Palase P.,
    7. Brennan F. R.,
    8. Hamilton W. D. O.,
    9. Bendahmane M.,
    10. Beachy R. N.
    Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection.FEMS Immunol. Med. Microbiol.272000291297
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Gilleland L. B.,
    2. Gilleland H. E. Jr.
    Synthetic peptides representing two protective, linear B-cell epitopes of outer membrane protein F of Pseudomonas aeruginosa elicit whole-cell-reactive antibodies that are functionally pseudomonad specific.Infect. Immun.63199523472351
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Harlow E.,
    2. Lane D.
    Antibodies: a laboratory manual 1988 471 510 Cold Spring Harbor Laboratory Cold Spring Harbor, N.Y
  25. 25.↵
    1. Hedstrom R. C.,
    2. Pavlovskis O. R.,
    3. Galloway D. R.
    Antibody response of infected mice to outer membrane proteins of Pseudomonas aeruginosa.Infect. Immun.4319844953
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Horan T. C.,
    2. White J. W.,
    3. Jarvis W. R.,
    4. Emori G.,
    5. Culver D. H.,
    6. Munn V. P.,
    7. Thornsberry C.,
    8. Olson D. R.,
    9. Hughes J. M.
    Nosocomial infection surveillance.Morb. Mortal. Wkly. Rep.3519861729
    OpenUrl
  27. 27.↵
    1. Hughes E. E.,
    2. Gilleland L. B.,
    3. Gilleland H. E. Jr.
    Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa.Infect. Immun.60199234973503
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Hughes E. E.,
    2. Gilleland H. E. Jr.
    Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa in a murine acute pneumonia model.Vaccine13199517501753
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Johnston S. A.,
    2. Tang D. C.
    Gene gun transfection of animal cells and genetic immunization.Methods Cell Biol.431994353365
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Knapp B.,
    2. Huntz E.,
    3. Lenz U.,
    4. Hungerer K.-D.,
    5. Gabelsberger J.,
    6. Domdey H.,
    7. Mansouri E.,
    8. Li Y.,
    9. von Specht B.-U.
    A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa.Vaccine17199916631666
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Le T. P.,
    2. Coonan K. M.,
    3. Hedstrom R. C.,
    4. Charoenvit Y.,
    5. Sedegah M.,
    6. Epstein J. E.,
    7. Kumar S.,
    8. Wang R.,
    9. Doolan D. L.,
    10. Maguire J. D.,
    11. Parker S. E.,
    12. Hobart P.,
    13. Norman J.,
    14. Hoffman S. L.
    Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.Vaccine18200018931901
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Lee N.,
    2. Ahn B.,
    3. Jung S. B.,
    4. Kim Y. G.,
    5. Kim H.,
    6. Park W. J.
    Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans.FEMS Immunol. Med. Microbiol.2720007985
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Lee N.,
    2. Jung S. B.,
    3. Ahn B. Y.,
    4. Kim Y. H.,
    5. Kim J.,
    6. Kim D.,
    7. Kim I.,
    8. Yoon S. M.,
    9. Nam S. W.,
    10. Kim H.,
    11. Park W. J.
    Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.Vaccine18200019521961
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Lee N.-G.,
    2. Ahn B. Y.,
    3. Jung S. B.,
    4. Lee Y.,
    5. Kim Y. G.,
    6. Kim H.-S.,
    7. Park W. J.
    Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa.FEMS Immunol. Med. Microbiol.251999339347
    OpenUrlPubMed
  35. 35.↵
    1. Leitner W. W.,
    2. Seguin M. C.,
    3. Ballou W. R.,
    4. Seitz J. P.,
    5. Schultz A. M.,
    6. Sheehy M. J.,
    7. Lyon J. A.
    Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites.J. Immunol.159199761126119
    OpenUrlAbstract
  36. 36.↵
    1. Luke C. J.,
    2. Carner K.,
    3. Liang X.,
    4. Barbour A. G.
    An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.J. Infect. Dis.17519979197
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Manickan E.,
    2. Karem K. L.,
    3. Rouse B. T.
    DNA vaccines—a modern gimmick or a boon to vaccinology? Crit. Rev. Immunol. 17 1997 139 154
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Mansouri E.,
    2. Gabelsberger J.,
    3. Knapp B.,
    4. Hundt E.,
    5. Lenz U.,
    6. Hungerer K.-D.,
    7. Gilleland H. E. Jr.,
    8. Staczek J.,
    9. Domdey H.,
    10. von Specht B.-U.
    Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.Infect. Immun.67199914611470
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Matthews-Greer J. M.,
    2. Gilleland H. E. Jr.
    Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.J. Infect. Dis.155198712821291
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Mutharia L. M.,
    2. Nicas T. I.,
    3. Hancock R. E. W.
    Outer membrane proteins of Pseudomonas aeruginosa serotype strains.J. Infect. Dis.1461982770779
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Okuda K.,
    2. Xin K. O.,
    3. Tsuji T.,
    4. Bukawa H.,
    5. Tanaka S.,
    6. Koff W. C.,
    7. Tani K.,
    8. Honma K.,
    9. Kawamoto S.,
    10. Hamajima K.,
    11. Fukushima J.
    DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity.Vaccine15199710491056
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Robinson H. L.
    Nucleic acid vaccines: an overview.Vaccine151997785787
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Sawa T.,
    2. Yahr T. L.,
    3. Ohara M.,
    4. Kurahashi K.,
    5. Gropper M. A.,
    6. Wiener-Kronish J. P.,
    7. Frank D. W.
    Active and passive immunization with Pseudomonas V antigen protects against type III intoxication and lung injury.Nat. Med.51999392398
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Sedegah M.,
    2. Jones T. R.,
    3. Kaur M.,
    4. Hedstrom R.,
    5. Hobart P.,
    6. Tine J. A.,
    7. Hoffman S. L.
    Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.Proc. Natl. Acad. Sci. USA95199876487653
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Smooker P. M.,
    2. Steeper K. R.,
    3. Drew D. R.,
    4. Strugnell R. A.,
    5. Spithill T. W.
    Humoral responses in mice following vaccination with DNA encoding glutathione S-transferase of Fasciola hepatica: effects of mode of vaccination and the cellular compartment of antigen expression.Parasite Immunol.211999357364
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Sokol P. A.,
    2. Kooi C.,
    3. Hodges R. S.,
    4. Cachia P.,
    5. Woods D. E.
    Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia.J. Infect. Dis.181200016821692
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Staczek J.,
    2. Gilleland H. E. Jr.,
    3. Gilleland L. B.,
    4. Harty R. N.,
    5. Garcia-Sastre A.,
    6. Engelhardt O. G.,
    7. Palese P.
    A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection.Infect. Immun.66199839903994
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Starke J. R.,
    2. Edwards M. S.,
    3. Langston C.,
    4. Baker C. J.
    A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia.Pediatr. Res.221987698702
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Tang D. C.,
    2. De Vit M.,
    3. Johnston S. A.
    Genetic immunization is a simple method for eliciting an immune response.Nature3561992152154
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Taubes G.
    Salvation in a snippet of DNA? Science 278 1997 1711 1714
    OpenUrlAbstract/FREE Full Text
  51. 51.
    1. Tuteja R.
    DNA vaccines: a ray of hope.Crit. Rev. Biochem. Mol. Biol.341999124
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Voller A.,
    2. Bidwell D. E.,
    3. Bartlett A.
    The enzyme linked immunosorbent assay. 1979 Dynatech Laboratories, Inc. Alexandria, Va
  53. 53.↵
    1. von Specht B.-U.,
    2. Christian L. H.,
    3. Blum B.,
    4. Schmitt A.,
    5. Hungerer K.-D.,
    6. Domdey H.
    Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers.Vaccine14199611111117
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    1. Waine G. J.,
    2. McManus D. P.
    Nucleic acids: vaccines of the future.Parasitol. Today111993113116
    OpenUrl
  55. 55.↵
    1. Yoshida A.,
    2. Nagata T.,
    3. Uchijima M.,
    4. Higashi T.,
    5. Koide Y.
    Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses.Vaccine18200017251729
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Protection against Pseudomonas aeruginosa Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of P. aeruginosa
Brian M. Price, Darrell R. Galloway, Neil R. Baker, Linda B. Gilleland, John Staczek, Harry E. Gilleland Jr.
Infection and Immunity May 2001, 69 (5) 3510-3515; DOI: 10.1128/IAI.69.5.3510-3515.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Protection against Pseudomonas aeruginosa Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of P. aeruginosa
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Protection against Pseudomonas aeruginosa Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of P. aeruginosa
Brian M. Price, Darrell R. Galloway, Neil R. Baker, Linda B. Gilleland, John Staczek, Harry E. Gilleland Jr.
Infection and Immunity May 2001, 69 (5) 3510-3515; DOI: 10.1128/IAI.69.5.3510-3515.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • Notes
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Bacterial Vaccines
Lung Diseases
Porins
Pseudomonas Infections
Pseudomonas aeruginosa
Vaccines, DNA

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522